Company intelligence / Profile preview

Sugarbreak

New York City, New York, United Statesx.com ↗

Ownership: Private
Development stage: Commercial

Overview

Sugarbreak offers a line of over-the-counter, plant-based products designed to help consumers reduce sugar consumption and maintain healthy blood sugar levels. Their portfolio includes supplements and functional foods such as Resist, Stabilize, Reduce, and Energize. These products are marketed as safe alternatives to pharmaceuticals for people seeking proactive wellness solutions related to blood glucose control[2][4][5].

Therapeutic areas: Endocrinology
Modalities: Non-pharmacological therapyNatural product (plant-based supplement)
Industry: Food & Nutrition

Drug pipeline

3 assets

Resist

Commercial

Indications: Sugar consumption reduction

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Sugarbreak.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sugarbreak.

Explore the full profile